Background/Aims: The incidence of Hepatitis B has significantly declined since the introduction of an HBV vaccination program. The aim of this study was to investigate recent clinical features of acute viral hepatitis B (AVH-B) in Korea. Methods: A total of 2241 patients with acute viral hepatitis were enrolled and their data were collected from nine medical-centers between January 2006 and December 2009. Results: One hundred nineteen (5.3%) of the 2241 were diagnosed as AVH-B. Among 78 patients with AVH-B whose data were analyzed, 50 were male, and the mean age was 38.6 years. In an initial test, mean AST, ALT and total-bilirubin levels were 1296.2 IU/L, 2109.6 IU/L and 9.3 mg/dl, respectively. Positivity frequencies for HBeAg and anti-HBe were 55.1% and 67.9%, respectively, and the mean HBV DNA level was 5.2 log10 copies/ml. The mean length of hospitalization was 11.6 days. During follow-up, AST, ALT and total bilirubin levels were normalized or near-normalized in all patients without serious complications. Sixty-three of 66 (95.4%) patients showed HBsAg loss and 37 (56.1%) patients showed HBsAg seroconversion. Only 3 patients (4.5%) showed persistent hepatitis B viremia. There was no case of death or liver transplantation. Nine patients (11.3%) had received anti-viral agents and their clinical outcomes were not significantly different from those of patients treated without antiviral agents. Conclusions: The prevalence of AVH-B among acute hepatitis patients is relatively low in Korea. AVH-B infection can be cured without complications in almost all patients, regardless of antiviral treatment. (Korean J Hepatol 2011;17:307-312)
INTRODUCTION
The incidence of acute viral hepatitis B (AVH-B) in the United States has declined steadily since the late 1980s. The reduction in hepatitis B virus (HBV) incidence in the US may be attributed to effective vaccination programs as well as universal precautions for needle use and in healthcare in general. 1 In Korea, an endemic area of HBV, the positivity of hepatitis B surface antigen (HBsAg) also decreased from 8% to 3.7%, since routine HBV vaccination program were introduced. 2 Several single-center studies showed that the etiology of acute viral hepatitis in Korea has been changing. 3, 4 Cases of AVH-B as the etiologic agent in acute viral hepatitis declined in the most recent decade. 3 Most primary infections of HBV are self-limited with clearance of virus and development of immunity. However, an estimated 3% to 5% of adults and up to 95% of children develop chronic HBV infection. 5 AVH-B can be symptomatic or asymptomatic.
In asymptomatic cases, biochemical abnormalities such as elevations of aminotransferase levels are usually undetected unless a routine check-up is performed. 6 In symptomatic cases, prodromal symptoms include general malaise, anorexia, nausea, vomiting and fever, which may last for several days to weeks. 6 Right upper quadrant discomfort or flu-like symptoms may also present. The patient may then be icteric or unicteric. 6 Approximately 1% of persons with AVH-B develop acute liver failure. 7 Although the epidemiology has changed, changes in the clinical courses of AVH-B have not been reported in Korea. Therefore, the aim of this study was to analyze data for prevalence and demographic and clinical characteristics of AVH-B in Korea.
PATIENTS AND METHODS

Study population
In this investigator-initiated cohort study, 2241 adult patients were diagnosed with acute viral hepatitis from Among them, 78 patients whose data could be investigated were included in this study and analyzed retrospectively. 
RESULTS
Baseline characteristics of the study population
A total of 2241 patients were diagnosed with acute viral hepatitis, and 119 (5.3%) of them were diagnosed with AVH-B (Fig. 1 ). Among the 119 AVH-B patients, 78 whose data could be investigated were enrolled. The baseline characteristics of the patients are shown in Table 1 . The mean age of patients was 38.6 years and the highest rate Clinical, biochemical and virologic profiles at the onset of AVH-B
All patients were HBsAg positive and IgM anti-HBc positive at presentation. Ten patients were anti-HBs positive.
Forty three (55.1%) patients were HBeAg positive and 53 (67.9%) patients were anti-HBe positive. The peak ALT levels ranged from 52 to 5477 IU/L, and the peak total bilirubin levels ranged from 0.8 to 33.8 mg/dL. The mean peak HBV DNA level were 5.2 log10 copies/mL and peak HBV DNA levels ranged from undetectable to 8.2 log10 copies/mL (Table 1) . Mean duration of hospitalization was 11.6 days.
Clinical, biochemical, and serologic profiles at follow-up 
Antiviral treatments and clinical courses
Nine (11.5%) patients among the 74 patients tested for serologic markers during the follow-ups had received antiviral agents (lamivudine for 3, entecavir for 4, and clevudine for 2). The mean duration of treatment was 10.3 months. At final follow-up, all patients showed normalization of ALT levels. Only 7 were examined for HBV serologic marker at The majority of acute hepatitis B cases in the early 1980s occurred in people aged 10-29 years. 12 The decline in the incidence of acute hepatitis B after the introduction of the HBV vaccination program was more striking in adults aged 10-29 years; these are individuals who were born after the introduction of HBV vaccination. 12 The incidence of acute hepatitis B has been changing in the early 2000s: it was highest among adults aged 30-39 years, who were born before the introduction of the HBV vaccination program. 4, 12 In this multicenter study, the mean age of patients was 38.6 years and the highest rate corresponds to the group aged 30-39 years. The age distribution of acute hepatitis B in our study was similar to that of a recent report by Yim et al. 4 Therefore, unvaccinated and uninfected adults may be vulnerable to AVH-B and require catch-up vaccination to protect against HBV infection.
Approximately 5% of all acute HBV infections progress to chronic infection, and the risk of progression from an acute to chronic phase is inversely proportional to age. 13 In the acute phase of HBV infection, the manifestations range from subclinical hepatitis to symptomatic hepatitis requiring hospitalization. The most serious form of presentation of acute hepatitis is fulminant hepatic failure with a fatality rate of 70%. 14 One study on the incidence of fulminant hepatitis in acute viral hepatitis B patients showed the incidence of fulminant hepatitis was 6.0%. 15 In this study, the symptoms of AVH-B improved in all patients, and there was no case of progression to fulminant hepatitis, death, and liver trans- and clinical improvement as compared to placebo in patients with acute hepatitis B. 18 In another study, early treatment with lamivudine led to a greater decrease in HBV DNA levels, better clinical improvement and lower mortality in patients with severe acute hepatitis B. 19 In our study, we compared HBsAg seroconversion rates, serum HBV DNAnegative rate, biochemical indicators, the incidence of liver failure and mortality between one group treated with antiviral agents and the other group without antiviral agents.
The clinical outcomes between the two groups were not significantly different. One reason for the lack of significant difference could be that no patient suffered from persistent hepatitis B viremia in the group treated with antiviral agent.
Limitations of our study include a small number of subjects and the retrospective design. Therefore, further evidence for antiviral agents in acute hepatitis B and fulminant hepatitis is required.
In conclusion, in this multi-center study, the prevalence of AVH-B among acute viral hepatitis patients is relatively low in Korea. The prognosis of patients with AVH-B is good in the majority of enrolled patients. However, some patients progress to a chronic state regardless of antiviral treatment.
Catch-up HBV vaccinations in adult population may be required to protect against HBV infection in Korea.
